Financial Performance Highlights

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹579.03 lacs
  • Total Income: ₹582.77 lacs (including Other Income of ₹3.74 lacs)
  • Total Expenses: ₹1,122.62 lacs
  • Employee Benefits: ₹283.35 lacs
  • Finance Costs: ₹190.18 lacs
  • Depreciation & Amortization: ₹160.54 lacs
  • Other Expenses: ₹359.08 lacs
  • Loss before tax: ₹(539.85) lacs
  • Net Loss: ₹(539.85) lacs
  • Basic & Diluted EPS: ₹(2.50) per share

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹1,277.38 lacs
  • Total Income: ₹1,296.77 lacs (including Other Income of ₹19.39 lacs)
  • Total Expenses: ₹2,085.10 lacs
  • Employee Benefits: ₹561.27 lacs
  • Finance Costs: ₹378.23 lacs
  • Depreciation & Amortization: ₹319.32 lacs
  • Other Expenses: ₹655.69 lacs
  • Loss before tax: ₹(788.33) lacs
  • Net Loss: ₹(788.33) lacs
  • Basic & Diluted EPS: ₹(3.66) per share

Comparative Performance

Quarterly Comparison (YoY):

  • Revenue increased from ₹416.74 lacs (Q2 FY2025) to ₹579.03 lacs (Q2 FY2026)
  • Loss reduced from ₹(614.28) lacs (Q2 FY2025) to ₹(539.85) lacs (Q2 FY2026)

Half-Yearly Comparison (YoY):

  • Revenue increased from ₹964.83 lacs (H1 FY2025) to ₹1,277.38 lacs (H1 FY2026)
  • Loss reduced from ₹(1,146.71) lacs (H1 FY2025) to ₹(788.33) lacs (H1 FY2026)

Balance Sheet Position (as at September 30, 2026)

  • Total Assets: ₹15,877.84 lacs
  • Non-current Assets: ₹15,095.06 lacs (mainly Property, Plant & Equipment: ₹13,917.55 lacs)
  • Current Assets: ₹782.78 lacs
  • Total Equity: Negative ₹(17,063.80) lacs
  • Equity Share Capital: ₹2,156.06 lacs
  • Other Equity: Negative ₹(19,219.86) lacs
  • Total Liabilities: ₹32,941.64 lacs
  • Non-current Liabilities: ₹20,341.25 lacs (including Borrowings: ₹15,450.00 lacs)
  • Current Liabilities: ₹12,600.39 lacs (including Borrowings: ₹7,248.56 lacs)

Cash Flow Statement (Half Year Ended September 30, 2026)

  • Net Cash from Operating Activities: ₹299.78 lacs
  • Net Cash used in Investing Activities: ₹(136.61) lacs
  • Net Cash used in Financing Activities: ₹(163.49) lacs
  • Net decrease in Cash: ₹(0.32) lacs
  • Cash & Cash equivalents at end: ₹12.59 lacs

Key Operational and Strategic Updates

1. Manufacturing Unit Status: The company's Vizag manufacturing unit remains closed since February 7, 2025, pursuant to an order by the Andhra Pradesh Pollution Control Board. The company is in constant dialogue with the Board for revocation of the closure order.

2. Amalgamation Approval: The Board of Directors approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited at their meeting held on June 26, 2026. The appointed date for the scheme of amalgamation is April 1, 2026, subject to necessary consents and approvals.

3. Segment Reporting: The company operates in one segment only, hence no segment results have been disclosed.

4. Subsidiaries: As of September 30, 2026, the company does not have any subsidiary, associate, or joint venture companies.

Audit and Compliance

  • The financial results were reviewed by the Audit Committee and approved by the Board of Directors
  • Statutory Auditors (Bhayani & Co., Chartered Accountants) issued an "Unmodified Report" on the results
  • Financial results prepared in accordance with Indian Accounting Standards (IND AS) and SEBI Listing Regulations
  • Figures of previous periods have been regrouped to conform to current period classification

Capital Structure

  • Paid-up Equity Share Capital: ₹2,156.06 lacs (Face Value ₹10 per share)
  • Net Worth (including Retained Earnings): Negative ₹(17,063.80) lacs as at September 30, 2026